Knockdown of DDX46 Inhibits the Invasion and Tumorigenesis in Osteosarcoma Cells
Open Access
- 13 March 2017
- journal article
- research article
- Published by Tech Science Press in Oncology Research
- Vol. 25 (3) , 417-425
Abstract
DDX46, a member of the DEAD-box (DDX) helicase family, is involved in the development of several tumors. However, the exact role of DDX46 in osteosarcoma and the underlying mechanisms in tumorigenesis remain poorly understood. Thus, in the present study, we explored the role of DDX46 in osteosarcoma and the underlying mechanisms. Our results demonstrated that the expression levels of DDX46 in both mRNA and protein were greatly elevated in human osteosarcoma tissues and cell lines. Knockdown of DDX46 obviously inhibited osteosarcoma cell proliferation and tumor growth in vivo. In addition, knockdown of DDX46 also significantly suppressed migration and invasion in osteosarcoma cells. Furthermore, knockdown of DDX46 substantially downregulated the phosphorylation levels of PI3K and Akt in SaOS2 cells. In summary, the present results have revealed that DDX46 plays an important role in osteosarcoma growth and metastasis. Knockdown of DDX46 inhibited osteosarcoma cell proliferation, migration, and invasion in vitro and tumor growth in vivo. Therefore, DDX46 may be a potential therapeutic target for the treatment of osteosarcoma.Keywords
This publication has 24 references indexed in Scilit:
- Knockdown of DDX46 inhibits proliferation and induces apoptosis in esophageal squamous cell carcinoma cellsOncology Reports, 2016
- Novel Biomarker Proteins in Chronic Lymphocytic Leukemia: Impact on Diagnosis, Prognosis and TreatmentPLOS ONE, 2016
- Osteosarcoma: Current Treatment and a Collaborative Pathway to SuccessJournal of Clinical Oncology, 2015
- Ddx46 Is Required for Multi-Lineage Differentiation of Hematopoietic Stem Cells in ZebrafishStem Cells and Development, 2013
- DEAD-Box Protein Ddx46 Is Required for the Development of the Digestive Organs and Brain in ZebrafishPLOS ONE, 2012
- Osteosarcoma: Review of the Past, Impact on the Future. The American Experience2009
- Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcomaCurrent Opinion in Oncology, 2007
- Biology and Therapeutic Advances for Pediatric OsteosarcomaThe Oncologist, 2004
- DEAD-box proteins: the driving forces behind RNA metabolismNature Reviews Molecular Cell Biology, 2004
- Characterization of novel SF3b and 17S U2 snRNP proteins, including a human Prp5p homologue and an SF3b DEAD-box proteinThe EMBO Journal, 2002